Topic: clinical trial data
Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.
The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH.
The strong early signs of efficacy led Regeneron to target a 2019 start date for a potentially registrational phase 2 study.
The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.
The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.
The FIX-Padua therapy achieved FIX activity levels of 23% to 37%, suggesting it is several times more effective than unIQure's old asset.
The data committee ruled Preob is unlikely to improve outcomes in patients with osteonecrosis, wiping 25% off Bone Therapeutics’ stock price.
U.K. government committee calls for increased transparency following report that half of clinical trials fail to publish results.
The highest dose of the anti-GM-CSF antibody failed to beat the placebo on a disease activity score, but GSK plans to run more trials nonetheless.
The trial linked the fixed-dose combination to a statistically significant improvement on a measure of patient disability.